Localized prostate cancer with pelvic arteriovenous malformation treated with low-dose-rate brachytherapy after transcatheter embolization: Two case reports.
arteriovenous malformation
definitive therapy
low‐dose‐rate brachytherapy
prostate cancer
transcatheter embolization
Journal
IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
24
08
2018
accepted:
14
01
2019
entrez:
4
8
2020
pubmed:
12
2
2019
medline:
12
2
2019
Statut:
epublish
Résumé
We describe two patients who underwent low-dose-rate prostate brachytherapy after embolization for pelvic arteriovenous malformation. Case 1: A 76-year-old man was referred for definitive treatment of intermediate-risk prostate cancer (prostate-specific antigen 8.667 ng/mL, cT2aN0M0, Gleason score 3 + 4 = 7). We planned low-dose-rate brachytherapy. However, magnetic resonance imaging and computed tomography demonstrated a large pelvic arteriovenous malformation. We performed embolization of the arteriovenous malformation before initiating treatment to lower the risk of rupture of the arteriovenous malformation during low-dose-rate brachytherapy. Case 2: A 69-year-old man was referred for the definitive treatment of high-risk prostate cancer (prostate-specific antigen 5.81 ng/mL, cT2aN0M0, Gleason score 4 + 4 = 8) with a pelvic arteriovenous malformation. Similar to Case 1, we performed embolization of the arteriovenous malformation before initiating treatment. In both cases, low-dose-rate brachytherapy could be performed without complications. Low-dose-rate brachytherapy after transcatheter embolization of pelvic arteriovenous malformations can safely and effectively treat localized prostate cancer with pelvic arteriovenous malformations.
Sections du résumé
BACKGROUND
BACKGROUND
We describe two patients who underwent low-dose-rate prostate brachytherapy after embolization for pelvic arteriovenous malformation.
CASE PRESENTATION
METHODS
Case 1: A 76-year-old man was referred for definitive treatment of intermediate-risk prostate cancer (prostate-specific antigen 8.667 ng/mL, cT2aN0M0, Gleason score 3 + 4 = 7). We planned low-dose-rate brachytherapy. However, magnetic resonance imaging and computed tomography demonstrated a large pelvic arteriovenous malformation. We performed embolization of the arteriovenous malformation before initiating treatment to lower the risk of rupture of the arteriovenous malformation during low-dose-rate brachytherapy. Case 2: A 69-year-old man was referred for the definitive treatment of high-risk prostate cancer (prostate-specific antigen 5.81 ng/mL, cT2aN0M0, Gleason score 4 + 4 = 8) with a pelvic arteriovenous malformation. Similar to Case 1, we performed embolization of the arteriovenous malformation before initiating treatment. In both cases, low-dose-rate brachytherapy could be performed without complications.
CONCLUSIONS
CONCLUSIONS
Low-dose-rate brachytherapy after transcatheter embolization of pelvic arteriovenous malformations can safely and effectively treat localized prostate cancer with pelvic arteriovenous malformations.
Identifiants
pubmed: 32743382
doi: 10.1002/iju5.12048
pii: IJU512048
pmc: PMC7292068
doi:
Types de publication
Case Reports
Langues
eng
Pagination
90-94Informations de copyright
© 2019 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Phys Med Biol. 2017 Jan 21;62(2):560-572
pubmed: 28033113
Pol J Radiol. 2015 Aug 13;80:388-90
pubmed: 26634010
Urology. 2011 Apr;77(4):986-90
pubmed: 21195465
BMC Cancer. 2017 Aug 25;17(1):573
pubmed: 28841855
Med Princ Pract. 2011;20(3):294-6
pubmed: 21455004
Radiat Oncol. 2014 May 06;9:107
pubmed: 24885896
J Vasc Surg. 2001 Jan;33(1):51-5
pubmed: 11137923
Eur Urol. 2002 Oct;42(4):407-12
pubmed: 12361908
Urol Case Rep. 2015 Aug 18;3(6):181-4
pubmed: 26793545
J Urol. 1998 Nov;160(5):1803
pubmed: 9783960
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285
pubmed: 28262473
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):505-16
pubmed: 25596107
BJU Int. 2012 Feb;109 Suppl 1:22-9
pubmed: 22239226
Urology. 2008 Dec;72(6):1359-61
pubmed: 18400274
Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1245-51
pubmed: 16253779
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1399-404
pubmed: 16029799